Stock NILE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Nile Therapeutics, Inc. Other OTC

Equities

US6541451018

End-of-day quote Other OTC
Other stock markets
- USD - Intraday chart for Nile Therapeutics, Inc.
Apr. 24 Capricor Therapeutics Gets Another Type-B Meeting With FDA for Duchenne Muscular Dystrophy Investigational Drug MT
Apr. 24 Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Capricor Therapeutics Gets Another Type-B Meeting With FDA for Duchenne Muscular Dystrophy Investigational Drug
MT
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy
AQ
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy
CI
Capricor Therapeutics to Present at Upcoming Investor Conferences
AQ
Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
AQ
Capricor Therapeutics, Inc. to Present Positive 24-Month Results from its HOPE-2 Open-Label Extension Study at 2024 Muscular Dystrophy Association Clinical & Scientific Conference
CI
Capricor: Q4 Earnings Snapshot
AQ
Transcript : Capricor Therapeutics, Inc., Q4 2023 Earnings Call, Feb 29, 2024
Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Posts Q4 Revenue $12.1M, vs. Street Est of $10.6M
MT
Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
AQ
Capricor Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Capricor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Sector Update: Health Care Stocks Ease Late Afternoon
MT
Sector Update: Health Care Stocks Decline Tuesday Afternoon
MT
Capricor Secures Meeting With FDA on CAP-1002 Manufacturing Plans; Shares Rise
MT
Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy
AQ
Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29
AQ
Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization
AQ
Capricor Therapeutics Announces Manufacturing Scale-Up of Cap-1002 Production At New San Diego Facility as It Continues Plans Toward Commercialization
CI
Capricor Therapeutics Shares Rise 7% After Collaboration for Covid-19 Vaccine
DJ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CAPR Stock
  4. Stock
  5. News Nile Therapeutics, Inc.